AI-Native Document Processing for Pharmaceuticals: Production in 6-10 Weeks

Audit-grade delivery for a regulated workflow

Most AI vendors approaching pharmaceuticals pitch a model and an integration story. The regulator pitches a different question: who owns the decision, who reviewed it, and can you reconstruct the reasoning six months later. Our engagement model is built around the regulator's question, not the vendor's pitch.

That means the architecture for document processing starts with the audit log, not the prompt. Every inference call is logged with its input context, retrieval bundle, model version, output, confidence band, downstream action, reviewer (if routed), and final disposition. The log is queryable on every dimension the regulator might ask about. Retention follows the longest plausible supervisory window for pharmaceuticals, which we capture during Discovery. The cost of this is a non-trivial slice of the Build budget — typically 15-20% — but the alternative is a workflow that cannot survive a serious examination, which is a cost we refuse to take.

The second design constraint is the human-in-the-loop boundary. For document processing in a regulated context, the binary "fully automated vs. fully manual" framing is wrong. We design three lanes: full automation for actions that are low-stakes, reversible, and high-confidence; drafted-with-review for actions that are higher-stakes but where a reviewer can validate quickly; reserved-to-human for actions that require judgment, escalation, or policy interpretation. The lanes are documented, the thresholds are calibrated against the labelled test set, and the boundaries are revisited quarterly as confidence data accumulates. This is the architecture that lets pharmaceuticals leadership tell a board, a regulator, and an auditor the same coherent story about how the workflow operates.

The single regulatory question that makes or breaks pharmaceuticals document processing engagements is "who is accountable for an automated decision". Our answer, baked into the architecture: there is always a named human owner per decision class, with the role visible in the reviewer interface, the audit log, and the governance map. Full automation does not mean no accountability — it means the named accountable human approved the policy that authorized the automation, and can revoke that authorization at any time without re-architecting the system.

Internal audit teams in pharmaceuticals are increasingly comfortable with AI in workflows, provided three conditions hold. The system is documented (model card, prompt repository, retrieval source list, threshold rationale). The decisions are traceable (audit log of inputs, outputs, model version, reviewer disposition). The controls are testable (the auditor can pull a random sample of cases and verify the workflow operated as documented). We engineer for all three from week one of Build because the alternative — retrofitting them into a working AI system — costs 4-6x as much and produces an inferior result.

What actually happens in the first month

What the first 30 days actually look like on document processing for pharmaceuticals is rarely communicated in vendor decks — so we describe it concretely here. Kickoff Monday: alignment on the labelled test set methodology, the integration scoping for CRM, the success metric definitions. By Wednesday, an initial 50-case labelled test set is in place, drafted by your operator team and reviewed by our delivery lead. By Friday, the retrieval index has its first batch of approved sources, indexed and queryable.

Week 2 is integration and prompt-strategy week. We connect to CRM, expand the labelled test set to 150+ cases, and ship the first prompt iteration against the harness. The Friday demo shows initial accuracy numbers on the test set — deliberately not impressive yet, but real. Week 3 is the action-layer week: draft generation, reviewer queue UI, audit log instrumentation. Friday demo shows the first end-to-end case flow.

Week 4 is the thin-slice production week. We deploy to a narrow audience (5-10% of routine cases), instrument the operator feedback loop, and run the first weekly performance review with your team. By end of day-30, the workflow is processing real pharmaceuticals traffic with the calibration loop closing, and the next phase of Build is scoped from concrete evidence.

The first 30 days of Build on document processing for pharmaceuticals follow a deliberate rhythm we have refined over multiple engagements. The pattern is not "deliver the whole workflow then test"; it is "deliver vertical slices, each production-ready, with the next slice scoped from the prior slice's evidence".

Slice 1 (week 1-2): the retrieval and intake layer running against a curated subset of your data, with the labelled test set captured and the eval harness wired up. Outcome: we can prove the system finds the right context for a representative range of pharmaceuticals cases. Slice 2 (week 3-4): the action layer drafting outputs that a reviewer approves before they hit production. Outcome: we can prove the system generates defensible drafts at a measurable accuracy rate. Slice 3 (week 5-6): low-confidence routing live, high-confidence automation gated by a calibration threshold. Outcome: we can prove the throughput-quality tradeoff is favourable on real production traffic. Subsequent slices widen the automation envelope, expand the integration surface, and add the reporting layer.

The vertical-slice cadence is what lets your team see compounding evidence rather than waiting for a big-bang reveal. It also lets us catch architectural issues early — week 2 evaluation results that surprise us are far cheaper to absorb than week 8 results. By the close of Build, every architectural choice has been validated against real pharmaceuticals data, not against a synthetic benchmark.